Janssen to bring Legend CAR T into clinic

Janssen Biotech Inc. said FDA cleared an IND for CAR T therapy JNJ-68284528 (LCAR-B38M) to treat multiple myeloma. Next half, the unit of Johnson & Johnson (NYSE:JNJ) expects to start a U.S. and

Read the full 332 word article

User Sign In